Cargando…

Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment

Detalles Bibliográficos
Autores principales:	Westhovens, R, van Riel, P, Sibilia, J, Vratsanos, G, Nuamah, I, Becker, JC
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833769/ http://dx.doi.org/10.1186/ar1128

Ejemplares similares

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
por: Genant, H K, et al.
Publicado: (2008)

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)
por: Smolen, Josef S., et al.
Publicado: (2015)

The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis
por: Ruderman, Eric M, et al.
Publicado: (2005)

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis
por: Westhovens, Rene, et al.
Publicado: (2015)

Development of Rheumatoid Arthritis in Cavitary Mycobacterium avium Pulmonary Disease: A Case Report of Successful Treatment with CTLA4-Ig (Abatacept)
por: Tanaka, Hiromu, et al.
Publicado: (2022)

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
por: Westhovens, R, et al.
Publicado: (2009)

CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients
por: Pieper, Jennifer, et al.
Publicado: (2013)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
por: Lundquist, Lisa M, et al.
Publicado: (2012)

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
por: Emery, P, et al.
Publicado: (2009)

Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
por: Emery, Paul, et al.
Publicado: (2023)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
por: Kremer, Joel M, et al.
Publicado: (2011)

Blood PD-1(+)TFh and CTLA-4(+)CD4(+) T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis
por: Aldridge, Jonathan, et al.
Publicado: (2021)

Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis
por: Guyot, Patricia, et al.
Publicado: (2011)

Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
por: Talmon, Maria, et al.
Publicado: (2023)

Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate
por: Benucci, Maurizio, et al.
Publicado: (2017)

Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis
por: Derambure, Céline, et al.
Publicado: (2020)

Abatacept: the evidence for its place in the treatment of rheumatoid arthritis
por: Köller, Marcus D.
Publicado: (2007)

The Use of Abatacept for the Treatment of Felty Syndrome in Rheumatoid Arthritis
por: Chin, Rishika V, et al.
Publicado: (2023)

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
por: Manders, Sofie HM, et al.
Publicado: (2015)

Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study
por: Jansen, Diahann T S L, et al.
Publicado: (2018)

Impact of Single-Nucleotide Polymorphisms of CTLA-4, CD80 and CD86 on the Effectiveness of Abatacept in Patients with Rheumatoid Arthritis
por: Marquez Pete, Noelia, et al.
Publicado: (2020)

PReS-FINAL-2327: Abatacept in the treatment of refractory uveitis
por: Moretti, D, et al.
Publicado: (2013)

Abatacept is effective in Chinese patients with LRBA and CTLA4 deficiency
por: Yang, Lu, et al.
Publicado: (2020)

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept
por: Ahmad, Harris A., et al.
Publicado: (2022)

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study
por: Muraoka, Sei, et al.
Publicado: (2021)

CTLA4-Ig Abatacept Ameliorates Proteinuria by Regulating Circulating Treg/IL-17 in Adriamycin-Induced Nephropathy Rats
por: Shuai, Lanjun, et al.
Publicado: (2020)

Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
por: Mathieu, Sylvain, et al.
Publicado: (2013)

Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis
por: Schiff, Michael, et al.
Publicado: (2016)

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study
por: Emery, Paul, et al.
Publicado: (2019)

Crosstalk between synovial fibroblasts and T lymphocytes in rheumatoid arthritis: effect of methotrexate
por: Miranda, E, et al.
Publicado: (2003)

Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis
por: Rexhepi, Sylejman, et al.
Publicado: (2012)

Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2015)

Experience with abatacept in refractory lupus nephritis
por: Calatayud, Emma, et al.
Publicado: (2023)

Short-chain methotrexate polyglutamate MTXPG2 as outcome parameter in rheumatoid arthritis
por: Hobl, Eva-Luise, et al.
Publicado: (2010)

A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations
por: Wells, Alvin F, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tdua703b4ic0b7phsvkghls7g5